Skip to main content

Table 2 Characteristics at time of AKI diagnosis in septic patients with and without AKI progression

From: Combining renal cell arrest and damage biomarkers to predict progressive AKI in patient with sepsis

Characteristics Overall (n = 149) Progression (n = 63) Non-Progression (n = 86) P
AKI Severity
 SCr at AKI diagnosis, mg/dL 1.6 ± 0.5 1.7 ± 0.5 1.5 ± 0.5 0.022
 Peak SCr, mg/dL 1.8 ± 0.8 2.2 ± 0.9 1.6 ± 0.5 < 0.001
 Change in SCr a, mg/dL 1.0 ± 0.6 1.3 ± 0.7 0.7 ± 0.4 < 0.001
 SCys-C at AKI diagnosis, mg/L 1.5 ± 0.7 1.7 ± 0.7 1.3 ± 0.7 0.004
 AKI stage 1, n (%) 123 (82.6) 53 (84.1) 70 (81.4) 0.664
 AKI stage 2, n (%) 26 (17.4) 10 (15.9) 16 (18.6) 0.664
 AKI duration, d 2.0 (1.0-4.0) 3.5 (2.0-5.0) 1.0 (1.0-3.0) < 0.001
Biomarkers at time of AKI diagnosis
 u[TIMP-2]*[IGFBP7], (μg/g Cr)2 1169.7 (426.6-3079.8) 2168.5 (1068.8-5274.9) 583.2 (293.6-1666.4) < 0.001
 uKIM-1, μg/g Cr 3.1 (1.5-6.0) 5.0 (2.7-7.3) 2.1 (0.8-4.8) < 0.001
 uIL-18, ng/g Cr 196.5 (79.5-664.5) 384.4 (89.4-1228.4) 131.5 (70.9-433.7) 0.017
 uACR, mg/g Cr 138.3 (47.8-476.5) 221.5 (76.6-546.2) 108.8 (33.9-302.3) 0.006
In-hospital outcomes
 ICU stay, d 7.0 (4.0-12.0) 7.0 (4.5-12.0) 6.0 (3.0-12.0) 0.296
 Acute dialysis, n (%) 23 (15.4) 23 (36.5) 0 (0.0) < 0.001
 In-hospital death, n (%) 45 (30.2) 45 (71.4) 0 (0.0) < 0.001
  1. AKI progression is defined as worsening of AKI stage
  2. a Serum creatinine level on the day of AKI diagnosis minus baseline serum creatinine level
  3. Abbreviation: SCr serum creatinine, SCys-C serum cystatin C. u[TIMP-2]*[IGFBP7], urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7; uKIM-1, urinary kidney injury moleculer-1; uIL-18, urinary Interleukin-18; uACR, urinary albumin to creatinine ratio